Nouvelles AMMs au niveau européen : le brexucabtagene autoleucel dans les lymphomes du manteau réfractaires aux inhibiteurs de tyrosine kinase de Bruton (BTK)
Authors:
- 30 January 2021
- journal article
- editorial
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (2) , 142-144
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2020
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)British Journal of Haematology, 2018
- Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working PartyBone Marrow Transplantation, 2018
- Mantle Cell LymphomaJournal of Clinical Oncology, 2016